Hims & Hers shares tumble
StockStory.org on MSN6h
Hims & Hers Health (NYSE:HIMS) Beats Q4 Sales Targets But Stock Drops 16%Telehealth company Hims & Hers Health (NYSE:HIMS) announced in Q4 CY2024, with sales up 95.1% year on year to $481.1 million.
Hims & Hers Health reports its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...
Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic ...
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
Hims & Hers Health beat fourth-quarter estimates and guided for better-than-expected revenue in the first quarter and 2025. The telehealth provider logged earnings of 11 cents a share on revenue of ...
Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
Analysts have recently evaluated Hims & Hers Health and provided 12-month price targets. The average target is $36.43, ...
Shares of Hims & Hers Health ( HIMS -25.79%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...
Hims & Hers Health (NYSE:HIMS – Get Free Report) is projected to announce its earnings results after the market closes on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results